Robert A. Dean

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Leslie M. Shaw, Hugo Vanderstichele, Małgorzata Knapik-Czajka et al. · Annals of Neurology · 2009 · 2.1K citations · Full text

Medicine, Neurology, Neuroscience +17

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Lawrence S. Honig, Bruno Vellas, Merçé Boada et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Medicine, Neurology, Pharmacology +17

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Eric Siemers, Karen Sundell, Christopher Carlson et al. · Alzheimer s & Dementia · 2015 · 365 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

Adam Fleisher, Rema Raman, Eric Siemers et al. · Archives of Neurology · 2008 · 331 citations · Full text

Medicine, Neurology, Pharmacology +17